Niacin and Chronic Kidney Disease

Area of Science:

• Nephrology
• Cardiology
• Biochemistry

Background:

• Chronic kidney disease (CKD) affects millions globally, with a significant portion of patients developing cardiovascular disease (CVD).
• CKD-mineral and bone disorder (CKD-MBD), driven by hyperphosphatemia, is a major contributor to CVD in CKD patients.
• Current treatments for hyperphosphatemia, like phosphate binders, have limitations and side effects.

Purpose of the Study:

• To explore the potential of niacin and related compounds in managing hyperphosphatemia and dyslipidemia in CKD patients.
• To investigate the dual therapeutic utility of niacin derivatives for preventing CVD in CKD.

Main Methods:

• Review of existing literature on CKD, CKD-MBD, hyperphosphatemia, dyslipidemia, and niacin/related compounds.
• Analysis of the mechanism of action of niacin in inhibiting intestinal phosphate transport.
• Examination of the role of niacin in managing dyslipidemia common in CKD patients.

Main Results:

• Hyperphosphatemia is a central risk factor for CKD-MBD and subsequent CVD.
• Dietary modifications alone are often insufficient to control phosphate levels in CKD.
• Niacin and related compounds can inhibit intestinal phosphate absorption and improve lipid profiles.

Conclusions:

• Niacin and related compounds offer a potential dual therapeutic approach for CKD patients.
• Targeting both hyperphosphatemia and dyslipidemia with niacin may help prevent CVD in CKD.
• Further research into niacin-based therapies could offer improved CVD prevention strategies for CKD patients.